Gatifloxacin


Full Generic Medicine Info
Dosage/Direction for Use

Ophthalmic
Bacterial conjunctivitis
Adult: As 0.3% solution: Instil 1 drop 2 hourly into the affected eye(s) while awake (Max: 8 times per day) on Days 1 and 2, then reduce to 1 drop up to 4 times daily on Days 3-7. As 0.5% solution: Instil 1 drop into the affected eye(s) 2 hourly while awake (Max: 8 times per day) on Day 1, then reduce to 1 drop 2-4 times daily on Days 2-7.
Child: ≥1 year As 0.5% solution: Same as adult dose.
Contraindications
Hypersensitivity to gatifloxacin or other quinolones.
Special Precautions
Not intended for direct application into the anterior chamber of the eye. Pregnancy and lactation. Patient Counselling Remove contact lenses before administration and wait for 10-15 minutes before reinserting soft contact lenses.
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. urticaria, itching); fungal or bacterial superinfection (prolonged use). Eye disorders: Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, worsening of conjunctivitis, eye pain. Gastrointestinal disorders: Dysgeusia.
Potentially Fatal: Hypersensitivity reactions including anaphylactic reactions, angioedema (including pharyngeal, laryngeal or facial oedema), or dyspnoea. Rarely, Stevens-Johnson syndrome.
Action
Gatifloxacin is a fluoroquinolone antibacterial that acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both DNA gyrase (an essential enzyme for bacterial replication, transcription and repair) and topoisomerase IV (an enzyme that plays a key role in bacterial cell division).
Storage
Ophthalmic: Store between 15-25°C. Protect from freezing.
CIMS Class
Eye Anti-Infectives & Antiseptics / Quinolones
ATC Classification
J01MA16 - gatifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
S01AE06 - gatifloxacin ; Belongs to the class of quinolone antiinfectives. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on gatifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in